StratifAI raises €12.5M to make cancer treatment more precise with AI

German startup StratifAI has secured € 12.5 million in funding, led by Picus Capital, co-led by Alven, alongside Heliad, Rubin Ritter, Lars Langusch, Jens Begemann and other existing investors including Debiopharm and Arve Capital.

Founded in 2023 in Dresden by Omar El Nahhas, Daniel Truhn, Jakob Nikolas Kather and Firas Khader, StratifAI was created to help doctors and researchers understand how individual patients might respond to cancer treatments. At the center of their work is Polaris, a data analysis platform that applies AI to large genetic and clinical datasets. By identifying biological signals linked to how patients react to specific drugs, the platform gives oncologists a clearer sense of which treatments are most likely to work best and why.

The new funding will not only help StratifAI expand clinical trials for Polaris, but also build research collaborations with cancer centers and grow its teams as it moves toward broader validation in Europe and the United States.

Sources: Stratifai | Startbase.com

Founders: Firas Khader, Omar El Nahhas, Daniel Truhn, Jakob Nikolas Kather